Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 11/2022

23-08-2022 | Prostate Cancer | Original Article

Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment

Authors: Tugba Akin Telli, Salih Ozguven, Ozkan Alan, Nuh Filizoglu, Mehmet Akif Ozturk, Nisanur Sariyar, Selver Isik, Rukiye Arikan, Nazim Can Demircan, Tugba Basoglu, Ilknur Alsan Cetin, Tunc Ones, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk

Published in: Annals of Nuclear Medicine | Issue 11/2022

Login to get access

Abstract

Objective

We aimed to evaluate whether baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment.

Materials and methods

This retrospective study included 54 mCRPC patients, who underwent baseline 68Ga-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of ≥ 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC.

Results

Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001–1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189–4.222, p = 0.01) as independent predictors of OS.

Conclusion

The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
3.
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, et al. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol. 2020;13(1):144.PubMedPubMedCentralCrossRef
4.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.PubMedCrossRef
5.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.PubMedCrossRef
6.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.PubMedCrossRef
7.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.PubMedCrossRef
8.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.PubMedPubMedCentralCrossRef
9.
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.PubMedCrossRef
10.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.PubMedCrossRef
11.
Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019;125:4172–80.PubMedCrossRef
12.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.PubMedCrossRef
13.
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.PubMed
14.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.PubMedCrossRef
15.
Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6.PubMedCrossRef
16.
Bagguley D, Ong S, Buteau JP, Koschel S, Dhiantravan N, Hofman MS, et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021;17(17):2225–41.PubMedCrossRef
17.
Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74(2):179–90.PubMedCrossRef
18.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.PubMedCrossRef
19.
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114–21.PubMedCrossRef
20.
Aksu A, Karahan Şen NP, Tuna EB, Aslan G, Çapa KG. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients [published correction appears in Nucl Med Commun. 2021 Oct 1;42(10):1186]. Nucl Med Commun. 2021;42(5):503–9.PubMedCrossRef
21.
Santos A, Mattiolli A, Carvalheira JB, Ferreira U, Camacho M, Silva C, et al. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):493–500.PubMedCrossRef
22.
Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019;33(5):344–50.PubMedCrossRef
23.
Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1862–72.PubMedCrossRef
24.
Karyağar S, Güven O, Karyağar SS, Arici S, Selvi O, Geredeli Ç, et al. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment? Nucl Med Commun. 2021;42(9):1011–6.PubMedCrossRef
25.
Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment. Hell J Nucl Med. 2021;24(1):25–35.PubMed
26.
Oruç Z, Güzel Y, Ebinç S, Kömek H, Küçüköner M, Kaplan MA, et al. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. Nucl Med Commun. 2021;42(12):1336–46.PubMedCrossRef
27.
Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200–10.PubMedCrossRef
28.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
29.
Hartrampf PE, Heinrich M, Seitz AK, et al. Metabolic tumour volume from PSMA PET/CT scans of prostate cancer patients during chemotherapy-do different software solutions deliver comparable results? J Clin Med. 2020;9:1390.PubMedCentralCrossRef
30.
Schmidkonz C, Cordes M, Goetz TI, et al. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33:766–75.PubMedCrossRef
31.
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962–8.PubMedCrossRef
32.
Kim YI, Lee HS, Choi JY. Prognostic significance of pretreatment 18F-FDG PET/CT volumetric parameters in patients with colorectal liver metastasis: a systematic review and meta-analysis. Clin Nucl Med. 2021;46(3):206–13.PubMedCrossRef
33.
Bouron C, Mathie C, Seegers V, Morel O, Jézéquel P, Lasla H, et al. Prognostic value of metabolic, volumetric and textural parameters of baseline [18F]FDG PET/CT in early triple-negative breast cancer. Cancers. 2022;14(3):637.PubMedPubMedCentralCrossRef
34.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.PubMedPubMedCentralCrossRef
35.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.PubMedCrossRef
36.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.PubMedPubMedCentralCrossRef
37.
Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9–15.PubMedCrossRef
38.
Tseng JR, Chang SH, Wu YY, et al. Impact of three-month androgen deprivation therapy on [68Ga]Ga-PSMA-11 PET/CT indices in men with advanced prostate cancer-results from a pilot prospective study. Cancers (Basel). 2022;14(5):1329.CrossRef
39.
Zhang Q, Han Y, Zhang Y, Liu D, Ming J, Huang B, Qiu X. treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol. 2021;1(10): 571308.CrossRef
40.
Okasho K, Ogawa O, Akamatsu S. Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Transl Androl Urol. 2021;10(10):3953–62.PubMedPubMedCentralCrossRef
41.
42.
Shen K, Liu B, Zhou X, et al. The evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancer. Front Oncol. 2021;11: 683793.PubMedPubMedCentralCrossRef
43.
Derlin T, Werner RA, Lafos M, et al. Neuroendocrine differentiation and response to PSMA-targeted radioligand therapy in advanced metastatic castration-resistant prostate cancer: a single-center retrospective study. J Nucl Med. 2020;61(11):1602–6.PubMedCrossRef
44.
Bakht MK, Hayward JJ, Shahbazi-Raz F, et al. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proc Natl Acad Sci USA. 2022;119(4): e2025710119.PubMedPubMedCentralCrossRef
Metadata
Title
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
Authors
Tugba Akin Telli
Salih Ozguven
Ozkan Alan
Nuh Filizoglu
Mehmet Akif Ozturk
Nisanur Sariyar
Selver Isik
Rukiye Arikan
Nazim Can Demircan
Tugba Basoglu
Ilknur Alsan Cetin
Tunc Ones
Ozlem Ercelep
Faysal Dane
Perran Fulden Yumuk
Publication date
23-08-2022
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 11/2022
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01785-x

Other articles of this Issue 11/2022

Annals of Nuclear Medicine 11/2022 Go to the issue

Short Communication

Attenuation correction for phantom tests: an alternative to maximum-likelihood attenuation correction factor-based correction for clinical studies in time-of-flight PET

Original Article

Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy

Original Article

PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model

Original Article

New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT

Original Article

Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose–positron emission tomography to differentiate between benign and malignant lesions

Original Article

Methods of calculating 123I-β-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy